Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01804101 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Liposomal Cytarabine-Daunorubicin CPX-351

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]